4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eton | NITISINONE | nitisinone | CAPSULE;ORAL | 216201-001 | May 25, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Medunik | NITISINONE | nitisinone | CAPSULE;ORAL | 212390-001 | May 26, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novitium Pharma | NITISINONE | nitisinone | CAPSULE;ORAL | 211041-001 | Aug 26, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Eton | NITISINONE | nitisinone | CAPSULE;ORAL | 216201-002 | May 25, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Medunik | NITISINONE | nitisinone | CAPSULE;ORAL | 212390-002 | May 26, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novitium Pharma | NITISINONE | nitisinone | CAPSULE;ORAL | 211041-002 | Aug 26, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Eton | NITISINONE | nitisinone | CAPSULE;ORAL | 216201-003 | May 25, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
